Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin

Endocrinology

Volumn 142, Issue 1, 2001, Pages 477-486

  Afargan, Michel ^e   Janson, Eva Tiensuu ^a   Gelerman, Garry ^e   Rosenfeld, Rakefet ^e   Ziv, Offer ^e   Karpov, Olga ^e   Wolf, Amnon ^f   Bracha, Moshe ^e   Shohat, Dvira ^e   Liapakis, George ^d   Gilon, Chaim ^b   Hoffman, Amnon ^c   Stephensky, David ^e   Oberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF CRETE   (Greece)

^e Peptor Ltd   (Israel)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLIC AMP; CYCLOPEPTIDE; FORSKOLIN; GLUCAGON; GROWTH HORMONE; INSULIN; OCTREOTIDE; PTR 3173; SMS 20199; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOID; CHO CELL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG URINE LEVEL; ENDOCRINE DISEASE; GLUCAGON RELEASE; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HUMAN; HUMAN CELL; INSULIN RELEASE; MALE; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

EID: 17744364678     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.1.7880     Document Type: Article

References (48)

1. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro
2. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
3. Molecular biology of somatostatin receptors
4. Characterization of cloned human somatostatin receptor SSTR5
5. Somatostatin receptor subtypes: Specific expression and signalling properties
6. Classification and nomenclature of somatostatin receptors
7. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2
8. Immunohistochemical localization of somatostatin receptor sst2A in the rat pancreas
9. Differential expression of five somatosatatin receptor subtypes, SSTR1-5 in the CNS and peripheral tissue
10. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic β-cells
11. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells
12. Backbone modifications in somatostatin analogues: Relation between conformation and activity
13. Octreotide
14. Relative potencies of the somatostatin analogs octreotide, BIM 23014 and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells
15. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
16. Effects of octreotide on glucaemic control, glucose disposal, hepatic glucose production and counter-regulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients
17. Somatostatin inhibits B-cell secretion via subtype-2 somatostatin receptor in the isolated perfused human pancreas
18. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
19. Drug-induced disorders of glucose metabolism. Mechanisms and management
20. Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose
21. Octreotide: A long-acting inhibitor of endogenous hormone secretion for human metabolic investigations
22. Backbone cyclization: A new method for conferring conformational constraint on peptides
23. In situ generation of protected amino acid chlorides using bis-(trichloromethyl)carbonate and its utilization for difficult couplings in solid phase peptide synthesis
24. A backbone-cyclic, receptor 5-selective somatostatin analogue: Synthesis, bioactivity, and nuclear magnetic resonance conformational analysis
25. Rapid identification of subtype selective agonists of somatostatin receptor through combinatorial chemistry
26. Characterization of cloned somatostatin receptors SSTR4 and SSTR5
27. Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells
28. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth
29. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
30. Peptide stability in drug development: In vitro peptide degradation in plasma and serum
31. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin
32. Modulation of A and B cell functions by tolbutamide and arginine in the pancreas of thiamine-deficient rats
33. A method for studying acute insulin secretion and glucose tolerance in unanaesthetised and unrestrained rats. The effect of mild stress on carbohydrate metabolism
34. Drugs interacting with G protein alpha subunits: Selectivity and perspectives
35. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin
36. Cross-competition between vasoactive intestinal peptide and somatostain for binding to tumor cell membrane receptors
37. Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors
38. Opiate antagonistic properties of an octapeptide somatostatin analog
39. Somatostatin analogs with affinity for opiate receptors in rat brain binding assay
40. The regulation of insulin and glucagon secretion by opiates: A study with naloxone in healthy humans
41. Multiple gene transcripts of the somatostatin receptor sstr2: Tissue selective distribution and cAMP regulation
42. Chemical structure, pharmacodynamic profile and pharmacokinetics of SMS 210-995 (Sandostatin)
43. Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization
44. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice
45. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs
46. Effect of opiate-receptor blockade on normoglycemic and hypoglycemic glucoregulation
47. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes
48. Growth hormone and somatostatin in glomerular injury